Article and Video CATEGORIES
What is the Role of Immunotherapy for Patients with Advanced NSCLC and a Driver Mutation?
Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Stan,
It's so good to hear you and yours are doing well and that you were able to spend time with both families for Thanksgiving. I know it meant a...
Hi Stan! It is good to hear from you -- I am so very happy you are doing well. I agree with Janine that family and friends - our chosen family...
Recent Comments
Hey Bluebird,
I understand…
I understand…
By JanineT GRACE … on
Thank you, Janine
By Bluebird on